Janakiram Murali, Pareek Vipul, Cheng Haiying, Narasimhulu Deepa M, Zang Xingxing
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Immunotherapy. 2016 Jun;8(7):809-19. doi: 10.2217/imt-2016-0001.
Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.
肿瘤免疫逃逸是癌症的标志之一，免疫检查点B7家族（PD-L1、PD-L2、B7-H3、B7x和HHLA2）的表达是肿瘤免疫逃逸以抑制T细胞功能的一种机制。阻断B7-1/B7-2/CTLA-4和PD-L1/PD-L2/PD-1这些相互作用的抗体在几种癌症中已取得显著的临床成功，且毒性低于传统化疗。尽管只有一小部分患者对检查点阻断有反应，但由于免疫记忆，这些有反应者的缓解持续时间显著，且比难治性疾病中使用任何其他药物预期的时间都要长。在本文中，我们综述了在人类肺癌和血液系统恶性肿瘤中阻断这些通路的治疗试验。
